Drugs / ASC42
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05464628 | Aug 2022 | — | Gannex Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05118516 | Nov → Dec 2021 | — | Gannex Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04965337 | Jul → Aug 2021 | — | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04679129 | Nov 2020 → May 2021 | — | Gannex Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05190523 | Apr 2022 → Mar 2024 | primary biliary cholangitis | Gannex Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05107778 | Jan 2022 → Nov 2023 | chronic hepatitis B virus infection | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASC42 | “One dose of oral ASC43F FDC tablet containing ASC41 5mg and ASC42 15mg.” NCT05118516 ↗ |
| Action | Activate | “farnesoid X receptor agonist” PMID 37919483 ↗ Nov 2023 |
| Route | Oral | “Oral tablets” NCT04679129 ↗ |